Top Suppliers:I want be here
Related CAS#:
404950-80-7 86405-09-6
441741-66-8 960055-56-5
922726-10-1 960055-68-9
960055-57-6 1158522-08-7
940364-43-2 134104-43-1
1895155-61-9 131615-57-1
1894948-35-6 6906-52-1
930439-75-1 1018584-77-4
1375289-11-4

404950-80-7

404950-80-7 structure
404950-80-7 structure
  • Name: Panobinostat (LBH589)
  • Chemical Name: panobinostat
  • CAS Number: 404950-80-7
  • Molecular Formula: C21H23N3O2
  • Molecular Weight: 349.426
  • Catalog: Biochemical Inhibitor Epigenetics HDAC inhibitor
  • Create Date: 2018-04-08 08:00:00
  • Modify Date: 2024-01-01 18:38:04
  • Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor.
Name panobinostat
Synonyms Panobinostat
(2E)-N-Hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
Farydak
LBH589
2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide
LBH-589
(E)-N-Hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide
Description Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor.
Related Catalog
Target

HDAC

In Vitro Panobinosta (LBH589) induces apoptosis of both MOLT-4 and Reh cells in a time- and dose-dependent manner. Panobinosta treatment results in histone (H3K9 and H4K8) hyperacetylation and regulation of cell-cycle control genes in Reh cells[1]. Panobinostat exhibites potent antiproliferative activity in human NSCLC cell lines with the IC50 ranging from 5 to 100 nM[2].
In Vivo Panobinosta (10, 20 mg/kg, i.p.) significantly slows tumor growth derived from Meso and NSCLC cells in vivo models. Panobinosta markedly increases acetylation of histone H3 and H4 of H69 human SCLC cells harvest from SCID mice[2]. Panobinostat (5, 10 and 20 mg/kg i.p.) demonstrates a clear benefit of decreased tumor burden, significantly improves TTE and reduces bone density loss in a disseminated multiple myeloma mouse model[3].
Cell Assay Cells are washed with ice-cold PBS containing 0.1 mM sodium orthovanadate, and total proteins are isolated using RIPA lysis buffer, which includes protease inhibitors (leupeptin, antipain, and aprotinin), 0.5 mM PMSF, and 0.2 mM sodium orthovanadate. Protein amounts are quantified using the Bio-Rad protein assay. Equal amounts of proteins are loaded onto an sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel, transferred onto nitrocellulose membrane, and probed with the antibody of interest: mouse monoclonal c-Myc and mouse monoclonal p21 antibodies; rabbit polyclonal phospho-Histone H2A.X, rabbit polyclonal acetyl-Histone H3 (Lys9), and rabbit polyclonal acetyl-Histone H4 (Lys8) antibodies; mouse monoclonal p27/KIP1 antibody; mouse monoclonal anti-β-actin; and mouse monoclonal anti-GADD45G. Membranes are then washed, reprobed with appropriate horseradish peroxidase-conjugated secondary antibodies, and developed with SuperSignal chemiluminescent substrate.
Animal Admin AE17 and TC-1 cancer cells (1×106 cells) are injected into the flanks of adult female C57Bl/6 mice and severe combined immunodeficiency (SCID) mice. M30 (10×106 cells), A549 (5×106 cells), H69 (2.5×106 cells), BK-T (6.5×106), H526 (10×106), and RG1 (10×106) cells are also injected, but in the presence of matrigel, into the flanks of SCID mice. When tumors reach 100 to 500 mm3, panobinostat is administered via i.p. injections (10-20 mg/kg) on a daily schedule (5-days-on, 2-days-off regimen) for the entire duration of the experiment. Control micereceive i.p. injections with dextrose 5% in water. Every tumor is measured with a caliper at least twice weekly. For evaluation of the effects of combination therapy on SCLC-derived tumors, SCID mice with H69 tumors are administered panobinostat. Three days after the initiation of panobinostat, and again 1 wk later, etoposide (40 mg/kg) is administered i.p.
References

[1]. Scuto A, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008 May 15;111(10):5093-100.

[2]. Crisanti MC, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8(8):2221-31.

[3]. Ocio EM, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95(5):794-803.
Density 1.2±0.1 g/cm3
Melting Point 114-117?C
Molecular Formula C21H23N3O2
Molecular Weight 349.426
Exact Mass 349.179016
PSA 77.15000
LogP 3.62
Index of Refraction 1.683
Storage condition -20°C Freezer, Under Inert Atmosphere
Hazard Codes Xi
Risk Phrases 22-36/37/38-20
Safety Phrases 24/25
HS Code 2933990090
441741-66-8 structure

441741-66-8

~%

404950-80-7 structure

404950-80-7

Literature: WO2007/21682 A1, ; Page/Page column 25-26 ;
960058-93-9 structure

960058-93-9

~%

404950-80-7 structure

404950-80-7

Literature: US2009/306405 A1, ; Page/Page column 5 ;
Precursor  1

DownStream  0

HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Chemsrc provides CAS#:404950-80-7 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 404950-80-7 | Chemsrc address: https://m.chemsrc.com/en/baike/1026767.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved